CLINICAL TRIALS PROFILE FOR FERRIC CITRATE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for FERRIC CITRATE
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT00967993 ↗ | Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease | Completed | Keryx Biopharmaceuticals | 2010-01-01 | The objective of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a dietary phosphate binder in controlling and managing serum phosphorus levels in patients with end-stage renal disease (ESRD). | |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for FERRIC CITRATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00648167 ↗ | A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) | Completed | Collaborative Study Group (CSG) | Phase 2 | 2008-03-01 | This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease. |
| NCT00648167 ↗ | A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) | Completed | Keryx Biopharmaceuticals | Phase 2 | 2008-03-01 | This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease. |
| NCT00967993 ↗ | Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease | Completed | Keryx Biopharmaceuticals | 2010-01-01 | The objective of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a dietary phosphate binder in controlling and managing serum phosphorus levels in patients with end-stage renal disease (ESRD). | |
| NCT01074125 ↗ | A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease | Completed | Collaborative Study Group (CSG) | Phase 3 | 2010-05-01 | This is a research study for people with high blood phosphorus levels who are on dialysis. This medical condition can cause weakening of the bones and damage other organs. This can lead to many health problems, and sometimes death. Phosphorus is in much of the food we eat, and is helpful to us in small amounts. Patients with kidney failure have trouble getting rid of the phosphorus eaten in food. Dialysis can help remove some of the phosphorus, but often patients must take a phosphate binder like PhosLo®, Renagel®, or Renvela® to bring the blood phosphorus levels back to normal. The purpose of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a phosphate binder. |
| NCT01074125 ↗ | A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease | Completed | Keryx Biopharmaceuticals | Phase 3 | 2010-05-01 | This is a research study for people with high blood phosphorus levels who are on dialysis. This medical condition can cause weakening of the bones and damage other organs. This can lead to many health problems, and sometimes death. Phosphorus is in much of the food we eat, and is helpful to us in small amounts. Patients with kidney failure have trouble getting rid of the phosphorus eaten in food. Dialysis can help remove some of the phosphorus, but often patients must take a phosphate binder like PhosLo®, Renagel®, or Renvela® to bring the blood phosphorus levels back to normal. The purpose of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a phosphate binder. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FERRIC CITRATE
Condition Name
Clinical Trial Locations for FERRIC CITRATE
Trials by Country
Clinical Trial Progress for FERRIC CITRATE
Clinical Trial Phase
Clinical Trial Sponsors for FERRIC CITRATE
Sponsor Name
